Cargando…

Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review

BACKGROUND: Personalized medicine is a growing area of research which aims to tailor the treatment given to a patient according to one or more personal characteristics. These characteristics can be demographic such as age or gender, or biological such as a genetic or other biomarker. Prior to utiliz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Antoniou, Miranta, Jorgensen, Andrea L, Kolamunnage-Dona, Ruwanthi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766245/ https://www.ncbi.nlm.nih.gov/pubmed/26910238 http://dx.doi.org/10.1371/journal.pone.0149803

Ejemplares similares

Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
por: Antoniou, Miranta, et al.
Publicado: (2017)

Correction: Antoniou, M.; et al. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J. Pers. Med. 2017, 7, 1
por: Antoniou, Miranta, et al.
Publicado: (2018)

Evaluating statistical characteristics of biomarker-guided trial designs
por: Antoniou, Miranta, et al.
Publicado: (2015)

Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size
por: Antoniou, Miranta, et al.
Publicado: (2017)

Correction: Antoniou, M.; et al. Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. J. Pers. Med. 2017, 7, 19
por: Antoniou, Miranta, et al.
Publicado: (2018)

Adjusting for informative missing outcome data in clinical trials with longitudinal study designs
por: Kolamunnage-Dona, Ruwanthi, et al.
Publicado: (2013)

Adaptive Signature Design- review of the biomarker guided adaptive phase –III controlled design
por: Bhattacharyya, Arinjita, et al.
Publicado: (2019)

Biomarker-guided trials: Challenges in practice
por: Antoniou, M., et al.
Publicado: (2019)

Bayesian joint modelling of longitudinal and time to event data: a methodological review
por: Alsefri, Maha, et al.
Publicado: (2020)

Joint modelling of time-to-event and multivariate longitudinal outcomes: recent developments and issues
por: Hickey, Graeme L., et al.
Publicado: (2016)

joineRML: a joint model and software package for time-to-event and multivariate longitudinal outcomes
por: Hickey, Graeme L., et al.
Publicado: (2018)

Sample size formula for joint modelling of longitudinal and time-to-event data in clinical trials
por: Powney, Matthew, et al.
Publicado: (2013)

Modelling variable dropout in randomised controlled trials with longitudinal outcomes: application to the MAGNETIC study
por: Kolamunnage-Dona, Ruwanthi, et al.
Publicado: (2016)

A review of the handling of missing longitudinal outcome data in clinical trials
por: Powney, Matthew, et al.
Publicado: (2014)

TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy
por: Pushpakom, Sudeep, et al.
Publicado: (2020)

Modelling of longitudinal data to predict cardiovascular disease risk: a methodological review
por: Stevens, David, et al.
Publicado: (2021)

Cardiovascular drugs and COVID‐19 clinical outcomes: a systematic review and meta‐analysis of randomized controlled trials
por: Asiimwe, Innocent G., et al.
Publicado: (2022)

Joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis
por: Sudell, Maria, et al.
Publicado: (2016)

Correction to: joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis
por: Sudell, Maria, et al.
Publicado: (2018)

Time-dependent ROC curve analysis in medical research: current methods and applications
por: Kamarudin, Adina Najwa, et al.
Publicado: (2017)

Cardiovascular drugs and COVID‐19 clinical outcomes: A living systematic review and meta‐analysis
por: Asiimwe, Innocent G., et al.
Publicado: (2021)

Phase II Trials in Drug Development and Adaptive Trial Design
por: Van Norman, Gail A.
Publicado: (2019)

An adaptive seamless phase II/III clinical trial design incorporating short-term endpoint information
por: Stallard, Nigel
Publicado: (2011)

Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy
por: Pushpakom, Sudeep P, et al.
Publicado: (2015)

Adjusting for treatment changes in epilepsy: causal analysis of randomised controlled trial survival outcomes in the presence of departure from randomised treatment
por: Dodd, Susanna, et al.
Publicado: (2013)

Investigation of 2‐stage meta‐analysis methods for joint longitudinal and time‐to‐event data through simulation and real data application
por: Sudell, Maria, et al.
Publicado: (2017)

Investigation of one‐stage meta‐analysis methods for joint longitudinal and time‐to‐event data through simulation and real data application
por: Sudell, Maria, et al.
Publicado: (2018)

Spatial and spatio-temporal statistical analyses of retinal images: a review of methods and applications
por: Zhu, Wenyue, et al.
Publicado: (2020)

Assessment and clinical course of hypocalcemia in critical illness
por: Steele, Tom, et al.
Publicado: (2013)

Using meta-analysis of Phase II trials to predict Phase III trial results
por: Burke, Danielle, et al.
Publicado: (2013)

Minimax and admissible adaptive two-stage designs in phase II clinical trials
por: Shan, Guogen, et al.
Publicado: (2016)

Optimal designs for phase II/III drug development programs including methods for discounting of phase II results
por: Erdmann, Stella, et al.
Publicado: (2020)

Using Bayesian adaptive designs to improve phase III trials: a respiratory care example
por: Ryan, Elizabeth G., et al.
Publicado: (2019)

Two Stage Designs for Phase III Clinical Trials
por: Follmann, Dean, et al.
Publicado: (2020)

Meta-analysis of randomized phase II trials to inform subsequent phase III decisions
por: Burke, Danielle L, et al.
Publicado: (2014)

Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
por: Davies, Geraint, et al.
Publicado: (2019)

A gated group sequential design for seamless Phase II/III trial with subpopulation selection
por: Miao, Guanhong, et al.
Publicado: (2023)

Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review
por: Palermos, Dionysios, et al.
Publicado: (2022)

Assessing the potential for outcome reporting bias in a review: a tutorial
por: Dwan, Kerry, et al.
Publicado: (2010)

BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials
por: Jiang, Liyun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f2j5g04trdjvmlr0so401k6qhr